Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 02 - 03 save search
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
Published: 2022-02-03 (Crawled : 23:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
restasis dry eye fda eye fda approval eye disease approval disease ophthalmic emulsion
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®
Published: 2022-02-03 (Crawled : 19:00) - biospace.com/
LPCN | $4.51 -6.04% -6.43% 66K
|
Health Technology
|
| O: 0.0%
H: 1.96%
C: -2.02%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: -1.45%
H: 1.47%
C: -0.29%
tlando fda fda acceptance submission resubmission
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®PDUFA target action date set for March 28, 2022
Published: 2022-02-03 (Crawled : 16:00) - biospace.com/
ATRS | $5.59 0.0%
|
Health Technology
|
| O: -1.45%
H: 1.47%
C: -0.29%
tlando fda fda acceptance pdufa set submission resubmission
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
Published: 2022-02-03 (Crawled : 14:30) - biospace.com/
CPRX | News | $15.12 2.65% 2.58% 940K
|
Health Technology
|
| O: -1.38%
H: 1.84%
C: -0.88%
ruzurgi fda als granted approval report grant
Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis
Published: 2022-02-03 (Crawled : 14:30) - biospace.com/
TMBR | $0.3426 -2.69% 3K
|
Health Technology
|
| O: 0.0%
H: 0.38%
C: -0.7%
tmb-001 fda phase 2 als positive
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
Published: 2022-02-03 (Crawled : 13:30) - biospace.com/
BCDA P | $0.376 -2.56% 64K
|
Health Technology
|
| O: 24.84%
H: 17.86%
C: 2.04%
fda heart device system cel therapy cardiamp designation
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
Published: 2022-02-02 (Crawled : 00:00) - biospace.com/
SYRS | $5.055 -1.65% -1.68% 90K
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
treatment fda drug orphan drug designation
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.